- Benchmark reported narrower losses in the third quarter of the year, as revenue was boosted by growth in its advanced nutrition business.

For the three months ended 30 June, pre-tax losses were £5.9 million compared with losses of £19.6 million a year earlier, as revenue increased 17% to £87.8 million.

Advanced nutrition, the company's largest business, grew revenue 15% above the prior year 'reflecting growth across all product lines,' the company said.

'We are very pleased with the results and progress in Q3 2021 and the subsequent period. Our three business areas performed strongly, and we achieved a major strategic milestone with the successful commercial launch of Ectosan Vet and CleanTreat,' the company said.

Looking ahead, the company said it was 'trading in line with market expectations for the full year with good revenue visibility for the remainder of the year.'

'Looking forward to FY 2022, consistency in performance is expected to continue in genetics and advanced nutrition, while health starts benefitting from Ectosan Vet and CleanTreat revenue stream,' it added.

Story provided by